Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae057 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yoshiya Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Fukuoka, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to assess the efficacy and safety of sarilumab in older patients with active rheumatoid arthritis (RA).
Methods
This is a post hoc analysis of KAKEHASI (NCT02293902) and HARUKA (NCT02373202) trials with stratification by age (<65 and ≥65 years). Patients with moderately to severely active RA were treated with sarilumab in combination with methotrexate or with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy. The primary end points in KAKEHASI and HARUKA trials were the American College of Rheumatology 20% improvement criteria (ACR20) responses at Week 24 and safety, respectively. Secondary end points were other RA disease activity measures, including Clinical Disease Activity Index (CDAI).
Results
Approximately 20% of patients were aged ≥65 years in treatment arms across both trials, except the sarilumab + csDMARD arm (40%, 12/30). ACR20 response rates were similar between age groups across sarilumab treatment arms, and similar results were obtained for the CDAI scores. Safety profiles were similar between age groups except for a higher incidence of serious adverse events in patients aged ≥65 years in the sarilumab + methotrexate arm.
Conclusions
In Japanese patients with RA enrolled in Phase 3 studies for sarilumab, no clear difference in efficacy or safety was observed between patients aged <65 and ≥65 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Fukuoka, Japan.
- Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
- Global Medical Affairs, Sanofi USA, Bridgewater, NJ, United States.
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
ORCID-Profile: Yoshiya Tanaka, Hideto Kameda
Zitieren
APA
Tanaka, Y., Takahashi, T., van Hoogstraten, H., Kato, N., & Kameda, H. (2024). Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (. Modern Rheumatology. https://doi.org/10.1093/mr/roae057
Vancouver
Tanaka Y, Takahashi T, van Hoogstraten H, Kato N, Kameda H. Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (. Modern Rheumatology. 2024. doi:10.1093/mr/roae057
BibTeX
@article{Tanaka2024,
author = {Tanaka, Yoshiya and Takahashi, Toshiya and van Hoogstraten, Hubert and Kato, Naoto and Kameda, Hideto},
title = {Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae057}
}
EUVIMED